Production (Stage)
Drugs Made In America Acquisition Corp.
DMAA
$10.18
-$0.01-0.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 330.90K | 279.90K | -- | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 330.90K | 279.90K | -- | ||
| Operating Income | -330.90K | -279.90K | -- | ||
| Income Before Tax | 1.25M | -279.90K | -- | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 1.25M | -279.90K | -- | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 1.25M | -279.90K | -- | ||
| EBIT | -330.90K | -279.90K | -- | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 0.05 | -0.03 | 0.00 | ||
| Normalized Basic EPS | 0.03 | -0.02 | -- | ||
| EPS Diluted | 0.05 | -0.03 | 0.00 | ||
| Normalized Diluted EPS | 0.03 | -0.02 | -- | ||
| Average Basic Shares Outstanding | 24.79M | 8.57M | -- | ||
| Average Diluted Shares Outstanding | 25.51M | 8.57M | -- | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||